Genprex, Inc., A Clinical-Stage Gene Therapy Company Focused On Developing Life-Changing Technologies For Patients With Cancer And Diabetes, Today Announced That The Company And A Major Cancer Research Center In Houston, Texas, In March 2021, Entered Into An Amendment (The &Ldquo;Amendment&Rdquo;) To Their May 2020 License Agreement (The &Ldquo;License Agreement&Rdquo;) To Grant To Genprex An Exclusive Worldwide License To An Additional Portfolio Of Six Patents And One Patent Application And Related Technology (&Ldquo;Newly Licensed Ip&Rdquo;). The Newly Licensed Ip Includes Methods For Treating Non-Small Cell Lung Cancer (Nsclc) By Administration Of A Tusc2 Therapeutic In Conjunction With Egfr Inhibitors Or Other Anti-Cancer Therapies, In Patients Who Are Predicted To Be Responsive To Tusc2 Therapy. A Tusc2 Gene-Expressing Plasmid Is The Active Agent In Reqorsa&Trade; Immunogene Therapy, Genprex&Rsquo;S Lead Drug Candidate.&Ldquo;We Are Pleased To Continue Optimizing And Expanding Our World-Class Intellectual Property Portfolio With The Addition Of These Technologies,&Rdquo; Said Rodney Varner, President And Chief Executive Officer Of Genprex. &Ldquo;These New Technologies Further Add To Our Arsenal Of Combination Therapies For Reqorsa, And May Enable Us To Improve Patient Outcomes Through The Advancement Of Multiple Therapeutic Approaches.&Rdquo;
